Lowest Price Guaranteed From USD 5,899
Published
August 2021
Pages
234
View Count
3834
-thumb.PNG) |
 |
 |
 |
 |
 |
 |
 |
 |
 |
According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains.
Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents. Presently, over 60 service providers are actively engaged in providing consumable / raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.
The “Cell Therapy Consumables Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial), Type of End-User (Industry and Non-Industry) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021 – 2031” report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:
One of the key objectives of the report was to estimate the existing market size and the future opportunity associated within the cell therapy consumables market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2021-2031. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of consumable (kits, media and reagents), [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), [C] scale of operation (clinical and commercial), [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of the cell therapy consumables market and its likely evolution in the short to mid-term and long-term.
Chapter 3 provides a general introduction to cell therapies. It further includes a detailed discussion on the development and manufacturing process of cell therapies, along with information on the role of raw materials in cell therapy manufacturing. Furthermore, it provides a brief overview of the different types of cell therapy consumables and key challenges associated with their development.
Chapter 4 provides a detailed overview of the cell therapy consumables landscape. It includes information related to over 60 industry players that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, location of headquarters, location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry).
Chapter 5 features an insightful company competitiveness analysis, highlighting prominent consumable service providers, taking into consideration service strength of a company (based on its experience and company size), product portfolio (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area) and number of products.
Chapter 6 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.
Chapter 7 provides elaborate profiles of key service providers (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.
Chapter 8 provides detailed analysis of the recent developments and initiatives (partnerships and collaborations, mergers and acquisitions and expansions) that have been undertaken in the cell therapy consumable industry, during the period between 2016 and 2021.
Chapter 9 features an in-depth analysis of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), manufacturing facilities and availability of other cell therapy capabilities.
Chapter 10 provides an informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on type of cell therapy and key geographical regions.
Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of cell therapy consumables market till 2031. We have segmented the market on the basis of [A] type of consumable (kits, media and reagents), [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), [C] scale of operation (clinical and commercial), [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).
Chapter 12 features an elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.
Chapter 13 highlights the effects of the recent COVID-19 pandemic on the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.
Chapter 14 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the cell therapy consumables market, based on the research and analysis described in the previous chapters.
Chapter 15 is a collection of transcripts of interviews conducted with various stakeholders in the industry.
Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Context and Background
3.2. Chapter Overview
3.3. Introduction to Cell Therapies
3.3.1. Comparison of Cell Therapies and Other Biotechnology Products
3.4. Classification of Cell Therapy Products
3.5. Overview of Cell Therapy Development and Manufacturing
3.6. Role of Raw Materials in Cell Therapy Development
3.7. Type of Cell Therapy Consumable
3.8. Key Challenges Associated with Cell Therapy Consumables
3.9. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell Therapy Kit Providers: List of Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Kits Preparation Facilities
4.2.5. Analysis by Accreditations Received
4.2.6. Analysis by Type of End-User
4.2.7. Analysis by Type of Cell Therapy
4.2.8. Analysis by Type of Function
4.2.9. Analysis by Scale of Operation
4.2.10. Analysis by Application Area
4.2.11. Analysis by Application Area and Geography (Regional Landscape)
4.3. Cell Therapy Media Providers: List of Players
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Location of Media Preparation Facilities
4.3.5. Analysis by Accreditations Received
4.3.6. Analysis by Type of End-User
4.3.7. Analysis by Type of Cell Therapy
4.3.8. Analysis by Media Components
4.3.9. Analysis by Type of Function
4.3.10. Analysis by Scale of Operation
4.3.11. Analysis by Application Area
4.3.12. Analysis by Application Area and Geography (Regional Landscape)
4.4. Cell Therapy Reagent Providers: List of Players
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Location of Reagent Preparation Facilities
4.4.5. Analysis by Accreditations Received
4.4.6. Analysis by Type of End-User
4.4.7. Analysis by Type of Cell Therapy
4.4.8. Analysis by Type of Function
4.4.9. Analysis by Scale of Operation
4.4.10. Analysis by Application Area
4.4.11. Analysis by Application Area and Geography (Regional Landscape)
4.5. Analysis by Type of Consumable, Type of Cell Therapy and Application Area (Grid Representation)
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Parameters
5.3. Methodology
5.4. Company Competitiveness: Kit Providers
5.5. Company Competitiveness: Media Providers
5.6. Company Competitiveness: Reagent Providers
6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Bio-Techne
6.4. Miltenyi Biotec
6.5. Sartorius
6.6. STEMCELL Technologies
6.7. Thermo Fisher Scientific
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Miltenyi Biotec
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. STEMCELL Technologies
7.3.1. Company Overview
7.3.2. Product Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. Bio-Techne
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Irvine Scientific
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. Thermo Fisher Scientific
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Sartorius
7.7.1. Company Overview
7.7.2. Product Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. BD Biosciences
7.8.1. Company Overview
7.8.2. Product Portfolio
7.8.3. Recent Developments and Future Outlook
7.9. Lonza
7.9.1. Company Overview
7.9.2. Product Portfolio
7.9.3. Recent Developments and Future Outlook
7.10. CellGenix
7.10.1. Company Overview
7.10.2. Product Portfolio
7.10.3. Recent Developments and Future Outlook
7.11. Corning
7.11.1. Company Overview
7.11.2. Product Portfolio
7.11.3. Recent Developments and Future Outlook
8. RECENT DEVELOPMENTS AND INITIATIVES
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell Therapy Consumables: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Consumable
8.3.5. Analysis by Type of Partnership and Type of Consumable
8.3.6. Analysis by Type of Cell Therapy
8.3.7. Analysis by Type of Consumable and Type of Cell Therapy
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Analysis by Region
8.3.9.1. Intracontinental and Intercontinental Agreements
8.3.9.2. Local and International Agreements
8.3.10. Cumulative Year-wise Trend of Merger / Acquisition
8.3.11. Analysis by Type of Acquisition
8.3.12. Analysis by Key Value Drivers
8.3.13. Analysis by Year of Acquisition and Key Value Drivers
8.4. Cell Therapy Consumables: Recent Expansions
8.4.1. Analysis by Year of Expansion
8.4.2. Analysis by Purpose of Expansion
8.4.3. Analysis by Year and Purpose of Expansion
8.4.4. Analysis by Type of Consumable
8.4.5. Analysis by Purpose of Expansion and Type of Consumable
8.4.6. Analysis by Area of Expansion
8.4.7. Analysis by Region
8.4.7.1. Analysis by Location of Consumable Facility (Continent-wise)
8.4.7.2. Analysis by Location of Consumable Facility (Country-wise)
8.4.8. Analysis by Purpose of Expansion and Location of Headquarters
9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS
9.1. Chapter Overview
9.2. Scoring Criteria and Key Assumptions
9.3. Scope and Methodology
9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers
9.3.1. Likely Partner Opportunities for Dendritic Cell Therapy Consumable Providers
9.3.2. Likely Partner Opportunities for NK Cell Therapy Consumable Providers
9.3.3. Likely Partner Opportunities for Stem Cell Therapy Consumable Providers
9.3.4. Likely Partner Opportunities for T-Cell Therapy Consumable Providers
10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Global Demand for Cell Therapy Consumables
10.4. Global Demand for Cell Therapy Consumables for Planar Processes
10.5. Global Demand for Cell Therapy Consumables for Suspension Processes
10.6. Analysis by Scale of Operation
10.7. Analysis by Region
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Global Outsourced Cell Therapy Consumables Market, 2021-2031
11.4. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Consumable
11.4.1. Outsourced Cell Therapy Consumables Market for Kits, 2021-2031
11.4.2. Outsourced Cell Therapy Consumables Market for Media, 2021-2031
11.4.3. Outsourced Cell Therapy Consumables Market for Reagents, 2021-2031
11.5. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Cell Therapy
11.5.1. Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, 2021-2031
11.5.2. Outsourced Cell Therapy Consumables Market for NK Cell Therapy, 2021-2031
11.5.3. Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, 2021-2031
11.5.4. Outsourced Cell Therapy Consumables Market for T-Cell Therapy, 2021-2031
11.6. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Scale of Operation
11.6.1. Outsourced Cell Therapy Consumables Market for Clinical Operations, 2021-2031
11.6.2. Outsourced Cell Therapy Consumables Market for Commercial Operations, 2021-2031
11.7. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of End-User
11.7.1. Outsourced Cell Therapy Consumables Market for Industry Players, 2021-2031
11.7.2. Outsourced Cell Therapy Consumables Market for Non-Industry Players, 2021-2031
11.8. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Geography
11.8.1. Outsourced Cell Therapy Consumables Market in North America, 2021-2031
11.8.2. Outsourced Cell Therapy Consumables Market in Europe, 2021-2031
11.8.3. Outsourced Cell Therapy Consumables Market in Asia-Pacific, 2021-2031
11.8.4. Outsourced Cell Therapy Consumables Market in Rest of the World, 2021-2031
12. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
12.1. Chapter Overview
12.2. Emerging Trends Related to Cell Culture Media
12.3. Automation of Cell Therapy Manufacturing Processes
12.4. Single Use Systems and Technologies in Cell Therapy Manufacturing
13. IMPACT OF COVID-19 ON CELL THERAPY CONSUMABLES MARKET
13.1. Chapter Overview
13.2. Impact of COVID-19 Pandemic on Cell Therapy Consumables Market
13.3. Impact on Future Market Opportunities for Cell Therapy Consumable Providers
13.4. Current Opinions and Key Initiatives of Key Players
13.5. Recuperative Strategies for Developer Businesses
13.5.1. Strategies for Implementation in the Short / Mid Term
13.5.2. Strategies for Implementation in the Long Term
14. CONCLUDING REMARKS
14.1. Chapter Overview
15. INTERVIEW TRANSCRIPTS
15.1. Chapter Overview
15.2. Anant Kamath, Chief Operating Officer, Cellular Engineering Technologies
15.2.1. Cellular Engineering Technologies: Key Highlights
15.2.2. Interview Transcript
15.3. Vishal G. Warke, Director R&D, Cell Culture and Immunology, HiMedia Laboratories and Gauri W. Page, Assistant R&D Manager, Animal Cell Culture, Himedia Laboratories
15.3.1. HiMedia Laboratories: Key Highlights
15.3.2. Interview Transcript
16. APPENDIX I: TABULATED DATA
17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Recent Developments
Figure 2.3 Executive Summary: Demand Analysis
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Type of Cell Therapy Consumable
Figure 4.1 Cell Therapy Consumables: Distribution by Type of Consumable
Figure 4.2 Cell Therapy Kit Providers: Distribution by Year of Establishment
Figure 4.3 Cell Therapy Kit Providers: Distribution by Company Size
Figure 4.4 Cell Therapy Kit Providers: Distribution by Location of Headquarters
Figure 4.5 Cell Therapy Kit Providers: Distribution by Location of Kit Preparation Facilities
Figure 4.6 Cell Therapy Kit Providers: Distribution by Accreditations Received
Figure 4.7 Cell Therapy Kit Providers: Distribution by Type of End-User
Figure 4.8 Cell Therapy Kits: Distribution by Type of Cell Therapy
Figure 4.9 Cell Therapy Kits: Distribution by Type of Function
Figure 4.10 Cell Therapy Kits: Distribution by Scale of Operation
Figure 4.11 Cell Therapy Kits: Distribution by Application Area
Figure 4.12 Regional Landscape: Distribution of Kit Providers by Application Area and Geography
Figure 4.13 Cell Therapy Media Providers: Distribution by Year of Establishment
Figure 4.14 Cell Therapy Media Providers: Distribution by Company Size
Figure 4.15 Cell Therapy Media Providers: Distribution by Location of Headquarters
Figure 4.16 Cell Therapy Media Providers: Distribution by Location of Media Preparation Facilities
Figure 4.17 Cell Therapy Media Providers: Distribution by Accreditations Received
Figure 4.18 Cell Therapy Media Providers: Distribution by Type of End-User
Figure 4.19 Cell Therapy Media: Distribution by Type of Cell Therapy
Figure 4.20 Cell Therapy Media: Distribution by Media Components
Figure 4.21 Cell Therapy Media: Distribution by Type of Function
Figure 4.22 Cell Therapy Media: Distribution by Scale of Operation
Figure 4.23 Cell Therapy Media: Distribution by Application Area
Figure 4.24 Regional Landscape: Distribution of Media providers by Application Area and Geography
Figure 4.25 Cell Therapy Reagent Providers: Distribution by Year of Establishment
Figure 4.26 Cell Therapy Reagent Providers: Distribution by Company Size
Figure 4.27 Cell Therapy Reagent Providers: Distribution by Location of Headquarters
Figure 4.28 Cell Therapy Reagent Providers: Distribution by Location of Reagent Preparation Facilities
Figure 4.29 Cell Therapy Reagent Providers: Distribution by Accreditations Received
Figure 4.30 Cell Therapy Reagent Providers: Distribution by Type of End-User
Figure 4.31 Cell Therapy Reagents: Distribution by Type of Cell Therapy
Figure 4.32 Cell Therapy Reagents: Distribution by Type of Function
Figure 4.33 Cell Therapy Reagents: Distribution by Scale of Operation
Figure 4.34 Cell Therapy Reagents: Distribution by Application Area
Figure 4.35 Regional Landscape: Distribution of Reagent Providers by Application Area and Geography
Figure 4.36 Grid Representation: Distribution by Type of Consumable, Type of Cell Therapy and Application Area
Figure 5.1 Company Competitiveness: Cell Therapy Kit Providers
Figure 5.2 Company Competitiveness: Cell Therapy Media Providers
Figure 5.3 Company Competitiveness: Cell Therapy Reagent Providers
Figure 6.1 Brand Positioning Matrix: Bio-Techne
Figure 6.2 Brand Positioning Matrix: Miltenyi Biotec
Figure 6.3 Brand Positioning Matrix: Sartorius
Figure 6.4 Brand Positioning Matrix: STEMCELL Technologies
Figure 6.5 Brand Positioning Matrix: Thermo Fisher Scientific
Figure 7.1 Miltenyi Biotec: Product Portfolio
Figure 7.2 STEMCELL Technologies: Product Portfolio
Figure 7.3 Bio-Techne: Product Portfolio
Figure 7.4 Irvine Scientific: Product Portfolio
Figure 7.5 Thermo Fisher Scientific: Product Portfolio
Figure 7.6 Sartorius: Product Portfolio
Figure 7.7 BD Biosciences: Product Portfolio
Figure 7.8 Lonza: Product Portfolio
Figure 7.9 CellGenix: Product Portfolio
Figure 7.10 Corning: Product Portfolio
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Consumable
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Consumable
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Consumable and Type of Cell Therapy
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 8.10 Partnerships and Collaborations: Local and International Agreements
Figure 8.11 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
Figure 8.12 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 8.13 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 8.14 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 8.15 Recent Expansions: Distribution by Year of Expansion
Figure 8.16 Recent Expansions: Distribution by Purpose of Expansion
Figure 8.17 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 8.18 Recent Expansions: Distribution by Type of Consumable
Figure 8.19 Recent Expansions: Distribution by Purpose of Expansion and Type of Consumable
Figure 8.20 Recent Expansions: Distribution by Area of Expansion
Figure 8.21 Recent Expansions: Distribution by Location of Consumable Facility (Continent-wise)
Figure 8.22 Recent Expansions: Distribution by Location of Consumable Facility (Country-wise)
Figure 8.23 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Figure 10.1 Global Demand for Cell Therapy Consumables, 2021-2026 (Million Liters)
Figure 10.2 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026 (Million Liters)
Figure 10.3 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026 (Million Liters)
Figure 10.4 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
Figure 10.5 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
Figure 10.6 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Region (Million Liters)
Figure 10.7 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Region (Million Liters)
Figure 11.1 Global Outsourced Cell Therapy Consumables Market, 2021-2031 (USD Million)
Figure 11.2 Outsourced Cell Therapy Consumables Market: Distribution by Type of Consumable
Figure 11.3 Outsourced Cell Therapy Consumables Market for Kits, 2021-2031 (USD Million)
Figure 11.4 Outsourced Cell Therapy Consumables Market for Media, 2021-2031 (USD Million)
Figure 11.5 Outsourced Cell Therapy Consumables Market for Reagents, 2021-2031 (USD Million)
Figure 11.6 Outsourced Cell Therapy Consumables Market: Distribution by Type of Cell Therapy
Figure 11.7 Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, 2021-2031 (USD Million)
Figure 11.8 Outsourced Cell Therapy Consumables Market for NK Cell Therapy, 2021-2031 (USD Million)
Figure 11.9 Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, 2021-2031 (USD Million)
Figure 11.10 Outsourced Cell Therapy Consumables Market for T-Cell Therapy, 2021-2031 (USD Million)
Figure 11.11 Outsourced Cell Therapy Consumables Market: Distribution by Scale of Operation
Figure 11.12 Outsourced Cell Therapy Consumables Market for Clinical Operations, 2021-2031 (USD Million)
Figure 11.13 Outsourced Cell Therapy Consumables Market for Commercial Operations, 2021-2031 (USD Million)
Figure 11.14 Outsourced Cell Therapy Consumables Market: Distribution by Type of End-User
Figure 11.15 Outsourced Cell Therapy Consumables Market for Industry Players, 2021-2031 (USD Million)
Figure 11.16 Outsourced Cell Therapy Consumables Market for Non-Industry Players, 2021-2031 (USD Million)
Figure 11.17 Outsourced Cell Therapy Consumables Market: Distribution by Region
Figure 11.18 Outsourced Cell Therapy Consumables Market in North America, 2021-2031 (USD Million)
Figure 11.19 Outsourced Cell Therapy Consumables Market in Europe, 2021-2031 (USD Million)
Figure 11.20 Outsourced Cell Therapy Consumables Market in Asia-Pacific, 2021-2031 (USD Million)
Figure 11.21 Outsourced Cell Therapy Consumables Market in Rest of the World, 2021-2031 (USD Million)
Figure 14.1 Concluding Remarks: Overall Market Overview
Figure 14.2 Concluding Remarks: Recent Developments
Figure 14.3 Concluding Remarks: Demand Analysis
Figure 14.4 Concluding Remarks: Market Sizing and Opportunity Analysis
Figure 14.5 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 3.1 Cell Therapies: Applications
Table 3.2 Differences between Cell Therapy and Biotechnology Product
Table 3.3 Key Cell Therapy Manufacturing Steps
Table 3.4 Types of Media Used in Cell Therapy Manufacturing
Table 7.1 Miltenyi Biotec: Key Highlights
Table 7.2 Miltenyi Biotec: Product Portfolio
Table 7.3 STEMCELL Technologies: Key Highlights
Table 7.4 STEMCELL Technologies: Product Portfolio
Table 7.5 STEMCELL Technologies: Recent Developments and Future Outlook
Table 7.6 Bio-Techne: Key Highlights
Table 7.7 Bio-Techne: Product Portfolio
Table 7.8 Bio-Techne: Recent Developments and Future Outlook
Table 7.9 Irvine Scientific: Key Highlights
Table 7.10 Irvine Scientific: Product Portfolio
Table 7.11 Irvine Scientific: Recent Developments and Future Outlook
Table 7.12 Thermo Fisher Scientific: Key Highlights
Table 7.13 Thermo Fisher Scientific: Product Portfolio
Table 7.14 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.15 Sartorius: Key Highlights
Table 7.16 Sartorius: Product Portfolio
Table 7.17 Sartorius: Recent Developments and Future Outlook
Table 7.18 BD Biosciences: Key Highlights
Table 7.19 BD Biosciences: Product Portfolio
Table 7.20 Lonza: Key Highlights
Table 7.21 Lonza: Product Portfolio
Table 7.22 CellGenix: Key Highlights
Table 7.23 CellGenix: Product Portfolio
Table 7.24 CellGenix: Recent Developments and Future Outlook
Table 7.25 Corning: Key Highlights
Table 7.26 Corning: Product Portfolio
Table 8.1 Cell Therapy Consumables: List of Partnerships and Collaborations, 2016-2021
Table 8.2 Cell Therapy Consumables Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise), 2016-2021
Table 8.3 Mergers and Acquisitions: Information on Key Value Drivers, 2016-2021
Table 8.4 Cell Therapy Consumables: List of Recent Expansions, 2016-2021
Table 9.1 Key Potential Strategic Partners for Cell Therapy Consumable Providers
Table 9.2 Likely Partners for Dendritic Cell Therapy Consumable Providers
Table 9.3 Likely Partners for NK Cell Therapy Consumable Providers
Table 9.4 Likely Partners for Stem Cell Therapy Consumable Providers
Table 9.5 Likely Partners for T-Cell Therapy Consumable Providers
Table 15.1 Cellular Engineering Technologies: Key Highlights
Table 15.2 HiMedia Laboratories: Key Highlights
Table 16.1 Cell Therapy Consumables: Distribution by Type of Consumable
Table 16.2 Cell Therapy Kit Providers: Distribution by Year of Establishment
Table 16.3 Cell Therapy Kit Providers: Distribution by Company Size
Table 16.4 Cell Therapy Kit Providers: Distribution by Location of Headquarters
Table 16.5 Cell Therapy Kit Providers: Distribution by Location of Kit Preparation Facilities
Table 16.6 Cell Therapy Kit Providers: Distribution by Accreditations Received
Table 16.7 Cell Therapy Kit Providers: Distribution by Type of End-User
Table 16.8 Cell Therapy Kits: Distribution by Type of Cell Therapy
Table 16.9 Cell Therapy Kits: Distribution by Type of Function
Table 16.10 Cell Therapy Kits: Distribution by Scale of Operation
Table 16.11 Cell Therapy Kits: Distribution by Application Area
Table 16.12 Cell Therapy Media Providers: Distribution by Year of Establishment
Table 16.13 Cell Therapy Media Providers: Distribution by Company Size
Table 16.14 Cell Therapy Media Providers: Distribution by Location of Headquarters
Table 16.15 Cell Therapy Media Providers: Distribution by Location of Media Preparation Facilities
Table 16.16 Cell Therapy Media Providers: Distribution by Accreditations Received
Table 16.17 Cell Therapy Media Providers: Distribution by Type of End-User
Table 16.18 Cell Therapy Media: Distribution by Type of Cell Therapy
Table 16.19 Cell Therapy Media: Distribution by Media Components
Table 16.20 Cell Therapy Media: Distribution by Type of Function
Table 16.21 Cell Therapy Media: Distribution by Scale of Operation
Table 16.22 Cell Therapy Media: Distribution by Application Area
Table 16.23 Cell Therapy Reagent Providers: Distribution by Year of Establishment
Table 16.24 Cell Therapy Reagent Providers: Distribution by Company Size
Table 16.25 Cell Therapy Reagent Providers: Distribution by Location of Headquarters
Table 16.26 Cell Therapy Reagent Providers: Distribution by Location of Reagent Preparation Facilities
Table 16.27 Cell Therapy Reagent Providers: Distribution by Accreditations Received
Table 16.28 Cell Therapy Reagent Providers: Distribution by Type of End-User
Table 16.29 Cell Therapy Reagents: Distribution by Type of Cell Therapy
Table 16.30 Cell Therapy Reagents: Distribution by Type of Function
Table 16.31 Cell Therapy Reagents: Distribution by Scale of Operation
Table 16.32 Cell Therapy Reagents: Distribution by Application Area
Table 16.33 Partnerships and Collaborations: Distribution by Year of Partnership
Table 16.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.35 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 16.36 Partnerships and Collaborations: Distribution by Type of Consumable
Table 16.37 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Consumable
Table 16.38 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Table 16.39 Partnerships and Collaborations: Distribution by Type of Consumable and Type of Cell Therapy
Table 16.40 Most Active Players: Distribution by Number of Partnerships
Table 16.41 Partnerships and Collaborations: Local and International Agreements
Table 16.42 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
Table 16.43 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 16.44 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 16.45 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 16.46 Recent Expansions: Distribution by Year of Expansion
Table 16.47 Recent Expansions: Distribution by Purpose of Expansion
Table 16.48 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 16.49 Recent Expansions: Distribution by Type of Consumable
Table 16.50 Recent Expansions: Distribution by Purpose of Expansion and Type of Consumable
Table 16.51 Recent Expansions: Distribution by Area of Expansion
Table 16.52 Recent Expansions: Distribution by Location of Consumable Facility (Continent-wise)
Table 16.53 Recent Expansions: Distribution by Location of Consumable Facility (Country-wise)
Table 16.54 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Table 16.55 Global Demand for Cell Therapy Consumables, 2021-2026 (Million Liters)
Table 16.56 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026 (Million Liters)
Table 16.57 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026 (Million Liters)
Table 16.58 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
Table 16.59 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
Table 16.60 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Region (Million Liters)
Table 16.61 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Region (Million Liters)
Table 16.62 Global Outsourced Cell Therapy Consumables Market, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.63 Outsourced Cell Therapy Consumables Market: Distribution by Type of Consumable, 2021 and 2030
Table 16.64 Outsourced Cell Therapy Consumables Market for Kits, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.65 Outsourced Cell Therapy Consumables Market for Media, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.66 Outsourced Cell Therapy Consumables Market for Reagents, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.67 Outsourced Cell Therapy Consumables Market: Distribution by Type of Cell Therapy, 2021 and 2030
Table 16.68 Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.69 Outsourced Cell Therapy Consumables Market for NK Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.70 Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.71 Outsourced Cell Therapy Consumables Market for T- Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.72 Outsourced Cell Therapy Consumables Market: Distribution by Scale of Operation, 2021 and 2030
Table 16.73 Outsourced Cell Therapy Consumables Market for Clinical Operations, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
Table 16.74 Outsourced Cell Therapy Consumables Market for Commercial Operations, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.75 Outsourced Cell Therapy Consumables Market: Distribution by Type of End-User, 2021 and 2030
Table 16.76 Outsourced Cell Therapy Consumables Market for Industry Players, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.77 Outsourced Cell Therapy Consumables Market for Non-Industry Players, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
Table 16.78 Outsourced Cell Therapy Consumables Market: Distribution by Geography, 2021 and 2030
Table 16.79 Outsourced Cell Therapy Consumables Market in North America, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
Table 16.80 Outsourced Cell Therapy Consumables Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
Table 16.81 Outsourced Cell Therapy Consumables Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
Table 16.82 Outsourced Cell Therapy Consumables Market in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
The following companies and organizations have been mentioned in the report.
Discounts available for multiple report purchases
sales@rootsanalysis.com